Literature DB >> 32371233

A Simple, Two-Step, Small-Scale Purification of Recombinant Adeno-Associated Viruses.

Shih-Heng Chen1, Amy Papaneri2, Mitzie Walker1, Erica Scappini3, Robert D Keys4, Negin P Martin5.   

Abstract

Recombinant adeno-associated viruses (rAAVs) are robust and versatile tools for in vivo gene delivery. Natural and designer capsid variations in rAAVs allow for targeted gene delivery to specific cell types. Low immunogenicity and lack of pathogenesis also add to the popularity of this virus as an innocuous gene delivery vector for gene therapy. rAAVs are routinely used to express recombinases, sensors, detectors, CRISPR-Cas9 components, or to simply overexpress a gene of interest for functional studies. High production demand has given rise to multiple platforms for the production and purification of rAAVs. However, most platforms rely heavily on large amounts of starting material and multiple purification steps to produce highly purified viral particles. Often, researchers require several small-scale purified rAAVs. Here, we describe a simple and efficient technique for purification of recombinant rAAVs from small amounts of starting material in a two-step purification method. In this method, rAAVs are released into the packaging cell medium using high salt concentration, pelleted by ultracentrifugation to remove soluble impurities. Then, the resuspended pellet is purified using a protein spin-concentrator. In this protocol, we modify the conventional rAAV purification methods to eliminate the need for fraction collection and the labor-intensive steps for evaluating the titer and purity of individual fractions. The resulting rAAV preparations are comparable in titer and purity to commercially available samples. This simplified process can be used to generate highly purified rAAV particles on a small scale, thereby saving resources, generating less waste, and reducing a laboratory's environmental footprint. Published by Elsevier B.V.

Entities:  

Keywords:  adeno-associated virus; gene delivery; neurobiology; rAAV; virus purification

Mesh:

Year:  2020        PMID: 32371233      PMCID: PMC7293145          DOI: 10.1016/j.jviromet.2020.113863

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  42 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

Review 2.  Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Authors:  Nathalie Clément; David R Knop; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

3.  rAAV-mediated tumorigenesis: still unresolved after an AAV assault.

Authors:  Paul N Valdmanis; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2012-11       Impact factor: 11.454

4.  Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

Authors:  Luca Perabo; Daniela Goldnau; Kathryn White; Jan Endell; Jorge Boucas; Sibille Humme; Lorraine M Work; Hanna Janicki; Michael Hallek; Andrew H Baker; Hildegard Büning
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Production and characterization of adeno-associated viral vectors.

Authors:  Joshua C Grieger; Vivian W Choi; R Jude Samulski
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Assessing the potential for AAV vector genotoxicity in a murine model.

Authors:  Hojun Li; Nirav Malani; Shari R Hamilton; Alexander Schlachterman; Giulio Bussadori; Shyrie E Edmonson; Rachel Shah; Valder R Arruda; Federico Mingozzi; J Fraser Wright; Frederic D Bushman; Katherine A High
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

7.  High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.

Authors:  E Ayuso; F Mingozzi; J Montane; X Leon; X M Anguela; V Haurigot; S A Edmonson; L Africa; S Zhou; K A High; F Bosch; J F Wright
Journal:  Gene Ther       Date:  2009-12-03       Impact factor: 5.250

8.  Cholinergic coordination of presynaptic and postsynaptic activity induces timing-dependent hippocampal synaptic plasticity.

Authors:  Zhenglin Gu; Patricia W Lamb; Jerrel L Yakel
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

Review 9.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.

Authors:  Michael F Naso; Brian Tomkowicz; William L Perry; William R Strohl
Journal:  BioDrugs       Date:  2017-08       Impact factor: 5.807

Review 10.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.

Authors:  Michaël Hocquemiller; Laura Giersch; Mickael Audrain; Samantha Parker; Nathalie Cartier
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.